Adaptive patient enrichment designs in therapeutic trials

Biometrical Journal

Volumn 51, Issue 2, 2009, Pages 358-374

  Wang, Sue Jane ^a   James Hung, H M ^a   O'Neill, Robert T ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Adaptive enrichment algorithm; Futility; Nested patient subset; Strong control of experiment wise type I error; Weighted Z statistic

Indexed keywords

CONTROLLED DRUG DELIVERY; MEDICAL APPLICATIONS;

ADAPTIVE ENRICHMENT ALGORITHM; CONTROL OF EXPERIMENTS; ENRICHMENT ALGORITHMS; FUTILITY; NESTED PATIENT SUBSET; STRONG CONTROL OF EXPERIMENT-WISE TYPE I ERROR; TREATMENT EFFECTS; TYPE-I ERROR; WEIGHTED Z-STATISTIC; Z-STATISTICS;

SET THEORY;

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ARTICLE; BREAST TUMOR; CLINICAL TRIAL; COMPUTER SIMULATION; FEMALE; HUMAN; PATIENT SELECTION; SAMPLE SIZE; STATISTICAL MODEL; STATISTICS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; FEMALE; HUMANS; MODELS, STATISTICAL; PATIENT SELECTION; SAMPLE SIZE;

EID: 66349125688     PISSN: 03233847     EISSN: 15214036     Source Type: Journal    
DOI: 10.1002/bimj.200900003     Document Type: Article

References (27)

1. Baselga, J. (2001). Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology 61, 14-21.
2. Bauer, P. and Kieser, M. (1999). Combining different phases in the development of medical treatments within a single trial. Statistics in Medicine 18, 1833-1848.
3. Bauer, P. and Kö hne, K. (1994). Evaluation of experiments with adaptive interim analyses. Biometrics 50, 1029-1041.
4. Bauer, P. and Kö nig, F. (2006). The reassessment of trial perspectives from interim data - a critical view. Statistics in Medicine 25, 23-36.
5. Bretz, F., Schmidli, H., Kö nig F., Racine A. and Maurer, W. (2006). Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts. Biometrical Journal 48, 623-634.
6. Cui, L., Hung, H. M. J., and Wang, S. J. (1999). Modification of sample size in group sequential clinical trials. Biometrics 55, 853-857.
7. Halperin, M., Lan, K. K. G., Ware, J. H., Johnson, N. J. and DeMets, D. L. (1982). An aid to data monitoring in long-term clinical trials. Controlled Clinical Trials 3, 311-323.
8. Henderson, I. C. and Patek A. J. (1998). The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Research Treatment 52, 261-288.
9. Hochberg, Y. (1988). A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75, 800-802.
10. Hollon, T. (2002). Impossible vaccine tames Staphylococcus aureus. The Scientist July 08, 24-28.
11. Hommel, G. (2001). Adaptive modifications of hypotheses after an interim analysis. Biometrical Journal 43, 581-589.
12. Huang, Y. and Hsu, J. C. (2007). Hochberg's step-up method: cutting corners off Holm's step-down method. Biometrika 94, 965-975.
13. Javinen, T. A., Tanner, M., Barlund, M., Borg, A. and Isola, J. (1999). Characterization of topoisomerase II alpha gene amplification and deletion in breast cancers. Genes Chromosomes Cancer 26 142-150.
14. Karlin, S. and Rinoot, Y. (1981). Total positivity properties of absolute value multinormal variables with applications to confidence interval estimates and related probabilistic inequalities. The Annals of Statistics 9, 1035-1049.
15. Marcus, R., Peritz, E. and Gabriel, K. R. (1976). On closed testing procedures with special reference to ordered analysis of variance. Biometrika 63, 655-660.
16. Paik, S., Bryant, J., Park, C., Fisher B. (1998). Erb-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. Journal of National Cancer Institute 90, 1361-1370.
17. Proschan, M., Lan, K. K. G. and Wittes J. (2006). Statistical Monitoring of Clinical Trials: A Unified Approach. Springer, New York, 60-61.
18. Sargent, D. J., Conley, B. A., Allegra, C. and Collette, L. (2005). Clinical trial designs for predictive marker validation in cancer treatment trials. Journal of Clinical Oncology 23, 2020-2027.
19. Simon, R. and Wang, S. J. (2006). Use of genomic signatures in therapeutics development in oncology and other diseases. The Pharmacogenomics Journal 6, 166-173.
20. Spiegelhalter, D. J., Freedman, L. S. and Blackburn, P. R. (1986). Monitoring clinical trials: conditional or predictive power? Controlled Clinical Trials 7, 8-17.
21. Tanner, M., Isola, J., Wiklund, T., Erikstein, B., Kellokumpu-Lehtinen, P., Malmstrom P., Wiling, N., Nilsson, J., and Bergh, J., (2006). Topoisomerase IIa gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER2/new-amplified breast cancer: Scandinavian Breast Group Trial 9401.
22. Temple, R. J. (2005). Enrichment designs: efficiency in development of cancer treatments. Journal of Clinical Oncology 23, 4838-4839.
23. Wang, S. J. (2006). Genomic biomarker derived therapeutic effect in pharmacogenomics clinical trials: a biostatistics view of personalized medicine. Taiwan Clinical Trials 4, 57-66.
24. Wang, S. J. (2007). Biomarker as a classifier in pharmacogenomics clinical trials: a tribute to 30th anniversary of PSI. Pharmaceutical Statistics 6, 283-296.
25. Wang, S. J. (2008). Adaptive strategy versus adaptive design in pharmacogenomics or pharmacogenetics clinical trials. Journal of the Formosan Medical Association 107, S18-S26.
26. Wang, S. J., Hung, H. M. J. and O'Neill, R. T. (2007a). Stagewise lanning for linical rials from hase II to hase III. Proceedings of the American Statistical Association, Biopharmaceutical Section [CD-ROM]. American Statistical Association, Alexandria, VA.
27. Wang, S. J., O'Neill, R. T. and Hung, H. M. J. (2007b). Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharmaceutical Statistics 6, 227-244.